

Indegene Ltd | BUY | Target Price | Rs: 610

Deal wins drive topline growth

We maintain **BUY** on Indegene with TP at Rs 610. Indegene reported strong topline growth on the back of deal wins (secured marquee deal wins, including two >US\$10m ACV contracts and one >US\$5m ACV engagement). It added 8 clients with US1mn+ revenue in Q3 along with adding 1-25 mn>\$+ client. Margins were impacted by one-time M&A and legal costs. We expect margins to normalize in the range of 18.5-19% over the next few quarters. PAT growth was flat to negative due to the amortization impact from the Biopharm deal (Rs 150 mn), this is expected to normalize by FY28e. **We continue to model mid-teens growth, supported by strong commercial execution, rising digital adoption across pharma, and a healthy deal pipeline.**

- Healthy topline growth supported by deal wins:** Indegene delivered robust revenue growth in Q3FY26, led by sustained momentum across its ECS and EMS segment. The co. continued to diversify its client portfolio, reducing top-client dependency (55% vs 58.9% from top 10 clients YoY). Indegene was able to convert 2 clients from 1-10 mn\$ to 10-25 mn\$, in-line with its efforts to mine existing clients. Tectonic contributed US\$1mn+ in Q3 (US\$2mn in H1FY26), with the entity converting multiple clients to paid contracts; initial deal values remain modest.
- Margins impacted by M&A costs, expected to normalize:** EBITDA margins were impacted in Q3 due to a one-time M&A integration and legal expenses (Rs 105 mn). Excluding these, core margins remained flattish YoY. We expect margins to gradually improve and stabilize at 18.5-19% over FY26-27e, supported by operating leverage and offshore mix improvement. Continued investments in GenAI and higher revenue contribution per employee (highest in the industry) are expected to enhance productivity and offset cost pressures.
- Outlook:** Indegene remains well-positioned to benefit from the increasing digital spend from Pharma and life science companies. Its strong client relationships (top 20 pharma companies), expanding service portfolio, and increasing focus on AI-driven solutions provide long-term visibility. With a healthy deal pipeline and a broadening geographic presence, we expect steady earnings growth over FY27-28e. We expect full impact of Biopharm's acquisition to be visible by FY28e.
- Valuations, view & risks:** We are factoring in 17.3%/18.2%/16.5% Revenue/EBITDA/PAT over FY25-FY28e, and value the company at 25x Q3FY28 PE, resulting in a TP of Rs 610. We believe the company can continue growing at mid-teens (without acquisitions) over the next 2 years, along with 18.5-19.5% margins and a strong balance sheet. Our base case estimates do not factor any acquisitions. **Key risks:** Increased competition globally, slower deal wins and mining of top 20 clients, and a delayed industry recovery.

Target Price	610	Key Data	
		Bloomberg Code	INDGN:IN
CMP	482	Curr Shares O/S (mn)	240
Upside	26.6%	Diluted Shares O/S(mn)	240
Price Performance (%)		Mkt Cap (Rsbn/USDmn)	115.9/1,263
		52 Wk H / L (Rs)	640/456
	1M	6M	1Yr*
INDGN:IN	-7.1	-11.0	-19.5
NIFTY	-2.4	2.2	8.9

Source: ACE Equity, Bloomberg, MNCL Research

Shareholding pattern (%)

Particulars	Dec-25	Sept-25	Jun-25	Mar-25
FIIs	11.5%	11.3%	10.0%	5.2%
DILs	8.1%	6.9%	7.2%	5.0%
Public	80.4%	81.7%	82.8%	89.8%

Source: BSE

Vinay Menon

vinay.menon@mnclgroup.com

NISM-201600112117

Miloni Mehta

miloni.mehta@mnclgroup.com

NISM-201800127664

Y/E Mar (Rs mn)	Revenue	YoY (%)	EBITDA	EBITDA (%)	Adj PAT	PAT(%)	Adj EPS	RoE (%)	RoCE (%)	P/E (x)	EV/EBITDA (x)
FY22	16,646	72.3%	2,869	17.2%	1,628	9.8%	7.4	21.3%	32.7%	97.5	40.1
FY23	23,061	38.5%	3,959	17.2%	2,661	11.5%	12.0	29.1%	30.1%	60.1	29.1
FY24	25,896	12.3%	5,054	19.5%	3,367	13.0%	14.0	27.0%	26.6%	34.4	22.7
FY25	28,393	9.6%	5,342	18.8%	4,067	14.3%	16.9	20.1%	20.7%	28.5	21.4
FY26E	34,871	22.8%	6,416	18.4%	4,366	12.5%	18.2	15.4%	18.1%	26.5	17.8
FY27E	40,507	16.2%	7,739	19.1%	5,299	13.1%	22.1	15.9%	18.6%	21.8	14.7
FY28E	45,773	13.0%	8,823	19.3%	6,431	14.1%	26.8	16.4%	18.7%	18.0	12.8

Source: Company, MNCL Research estimate

Conference call highlights

- Indegene delivered a strong Q3 FY26, with revenue at USD 94.2 million, growing 30.8% YoY and 17.1% QoQ, reflecting sustained momentum across segments.
- The company has secured multiple deal wins with cumulative revenue potential exceeding USD 10 million, expected to start contributing from Q2 FY27 onwards.
- Omnichannel operations crossed USD 1 billion in value, underscoring successful scale-up and deepening client adoption across global pharma customers.
- A large USD 20 billion TCV deal was signed with a mid-sized biotech, highlighting Indegene's ability to win transformational, enterprise-scale engagements.
- GenAI is emerging as a key growth driver, forming a significant part of recent wins and expected to generate ~USD 5 million revenue in the first month of implementation for select clients.
- A multi-year global AI automation deal with USD 7.5 million TCV is scheduled to go live in January 2026, adding to medium-term revenue visibility.
- Structural industry trends remain favorable, with management expecting 5–8% industry CAGR through CY2029, supported by declining revenue per drug and rising demand for cost-efficient, indigenous content solutions.
- Top 20 global pharmaceutical clients have adopted Indegene's omnichannel framework, with two large omnichannel deal wins recorded during the quarter.
- Integration of recent acquisitions is progressing well, with cost synergies of ~USD 1 million per quarter already identified and under execution.
- EBITDA margins were temporarily impacted by plant investments and upfront deal ramp-up costs, but management reiterated confidence of margins returning to ~20% over the next 6–8 quarters, starting Q1 FY27.
- Cash flow generation remains strong, with OCF/PAT exceeding 150%, driven by non-cash charges; accounting remains conservative with no cash flow impact.
- Management highlighted continued focus on GenAI upskilling and enterprise-wide AI deployment, positioning Indegene for sustained, profitable growth over the long term.

Comments

- We expect depreciation to trim down over the next 4-6 quarters as per the amortization schedule given by the company.
- We expect EPS growth to be 20%+ over the next 2 years on the back of strong deal wins, margin expansion and robust cash generation. Margins should be back in the 19-20% range by end of FY27e.

Quarterly forecast

Y/E March (Rs mn)	Mar-26e	Jun-26e	Sep-26e	Dec-26e	Mar-27e	Jun-27e	Sep-27e	Dec-27e
Net sales	9,800	9,345	9,827	10,457	10,878	10,560	11,104	11,817
QoQ growth	4%	-5%	5%	6%	4%	-3%	5%	6%
YoY growth	30%	23%	22%	11%	11%	13%	13%	13%
EBITDA	1,862	1,776	1,818	2,031	2,114	2,052	2,047	2,309
EBITDA Margin (%)	19.0	19.0	18.5	19.4	19.4	19.4	18.4	19.5
Other income	139	220	250	250	283	310	340	344
Depreciation	429	410	410	365	365	375	375	369
EBIT	1,572	1,586	1,658	1,916	2,032	1,987	2,012	2,284
EBIT Margin (%)	16.0%	17.0%	16.9%	18.3%	18.7%	18.8%	18.1%	19.3%
Profit Before Tax	1,537	1,553	1,625	1,885	2,002	1,959	1,985	2,259
Tax	384	388	406	471	501	490	496	565
Net profit	1,153	1,164	1,219	1,414	1,502	1,469	1,489	1,694

Source: MNCL Research Estimates

Quarterly financials

Exhibit 1: Quarterly Financials

Y/E March (Rs mn)	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Particulars								
Net sales	6,730	6,765	6,868	7,204	7,556	7,608	8,042	9,421
Manufacturing Expenses	1,059	1,033	1,187	1,448	1,230	1,240	1,478	2,146
Employee cost	4,284	4,443	4,420	4,438	4,851	4,815	5,158	5,680
Operating EBITDA	1,387	1,289	1,261	1,318	1,475	1,553	1,406	1,595
Other Income	232	225	214	377	256	221	197	194
EBIT	1434	1313	1281	1495	1524	1558	1,369	1,393
Depreciation	185	201	194	200	207	216	234	396
Interest	123	117	40	32	31	37	38	46
PBT	1,335	1,196	1,241	1,463	1,493	1,521	1,331	1,347
Tax	387	319	324	366	317	357	310	318
Profit After Tax	948	877	917	1,097	1,176	1,164	1,021	1,029
<hr/>								
Growth (%)								
Revenue	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%	-0.1%
EBITDA	-6.9%	-7.1%	-2.2%	4.5%	11.9%	5.3%	-9.5%	13.4%
PAT	-4.0%	-7.5%	4.6%	19.6%	7.2%	-1.0%	-12.3%	0.8%
<hr/>								
Margin (%)								
EBITDA	20.6%	19.0%	18.3%	18.3%	19.5%	20.4%	17.5%	16.9%
EBIT	21.3%	19.4%	18.7%	20.8%	20.2%	20.5%	17.0%	14.8%
PAT	14.1%	12.9%	13.6%	15.2%	15.6%	15.3%	12.7%	10.9%

Source: Company, MNCL Research

Financials

Exhibit 2: Income Statement

Y/E March (Rs mn)	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Net Revenues	16,646	23,061	25,896	28,393	34,871	40,507	45,773
Employee Cost	10,143	14,648	16,516	18,152	21,729	25,469	28,711
<i>% of revenues</i>	60.9%	63.5%	63.8%	63.9%	62.3%	62.9%	62.7%
Others	3,515	4,241	4,109	4,437	6,726	7,291	8,239
<i>% of revenues</i>	21.1%	18.4%	15.9%	15.6%	19.3%	18.0%	18.0%
EBITDA	2,869	3,959	5,054	5,342	6,416	7,739	8,823
EBITDA margin (%)	17.2%	17.2%	19.5%	18.8%	18.4%	19.1%	19.3%
Depreciation & Amortisation	335	598	761	802	1,275	1,550	1,487
Other income	259	582	763	1,072	751	1,003	1,344
EBIT	2,794	3,943	5,056	5,612	5,892	7,192	8,680
Net interest cost	60	313	494	220	156	127	105
Exceptional items	-4,690	0	0	0	0	0	0
PBT	-1,956	3,630	4,562	5,392	5,736	7,065	8,575
Taxes	637	969	1,219	1,326	1,369	1,766	2,144
<i>Effective tax rate (%)</i>	-33%	27%	27%	25%	24%	25%	25%
Reported PAT	1,628	2,661	3,367	4,067	4,366	5,299	6,431

Source: Company, MNCL Research estimates

Exhibit 3: Key Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Growth Ratio (%)							
Revenue	72.3%	38.5%	12.3%	9.6%	22.8%	16.2%	13.0%
EBITDA	24.5%	38.0%	27.7%	5.7%	20.1%	20.6%	14.0%
Adjusted PAT	63.4%	26.5%	20.8%	7.4%	21.4%	21.4%	21.9%
Margin Ratios (%)							
EBITDA	17.2%	17.2%	19.5%	18.8%	18.4%	19.1%	19.3%
PBT from operations	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Adjusted PAT	9.8%	11.5%	13.0%	14.3%	12.5%	13.1%	14.1%
Return Ratios (%)							
ROE	21.3%	29.1%	27.0%	20.1%	15.4%	15.9%	16.4%
ROCE	32.7%	30.1%	26.6%	20.7%	18.1%	18.6%	18.7%
Turnover Ratios (days)							
Debtors	97	102	91	97	95	94	94
Inventory	0	0	0	0	0	0	0
Creditors	27	18	26	19	18	17	17
Cash conversion cycle	71	83	65	78	77	77	77
Solvency Ratio (x)							
Current Ratio	2.6	3.0	2.9	4.5	5.1	4.3	4.8
Per share Ratios (Rs)							
Adjusted EPS	7.4	12.0	14.2	16.9	18.2	22.1	26.8
BVPS	34.8	48.1	59.5	108.9	127.3	149.5	176.5
Valuation (x)*							
P/E	97.5	60.1	34.4	28.5	26.5	21.8	18.0
P/BV	137.9	10.0	8.1	4.4	3.8	3.2	2.7
EV/EBITDA	40.1	29.1	22.7	21.4	17.8	14.7	12.8

Source: Company, MNCL Research estimates

Exhibit 4: Balance Sheet

Y/E March (Rs mn)	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
SOURCES OF FUNDS							
Equity Share Capital	4	443	444	479	479	479	479
Reserves & surplus	7,636	10,195	13,847	25,677	30,079	35,418	41,893
Shareholders' fund	7,639	10,638	14,291	26,156	30,558	35,897	42,372
Minority Interest							
Def tax liab. (net)	(692)	(671)	(708)	(898)	(898)	(898)	(898)
Other Liabilities	5,044	6,725	6,553	6,169	4,720	7,751	8,955
Total Liabilities	12,843	21,368	24,748	32,361	36,100	44,636	52,561
Net Block	766	1,272	1,326	5,040	5,140	5,340	5,340
Goodwill	679	855	3,160	3,160	3,160	3,160	3,160
Non-current assets	1,543	6,881	6,840	7,061	12,542	11,952	11,326
Inventories	-	-	-	-	-	-	-
Sundry debtors (current)	4,439	6,420	6,480	7,514	9,076	10,432	11,788
Cash	5,173	858	1,910	3,746	7,501	11,488	18,932
Loans & Advances	65	362	339	601	800	920	1,050
Other assets	425	707	1,214	542	1,150	1,126	1,280
Total Current Asset	11,300	14,487	17,908	25,300	23,559	32,685	41,235
Trade payables	742	733	1,181	934	1,720	1,887	2,132
Other current Liab.	3,055	3,543	4,025	3,953	2,100	4,700	5,500
Net Current Assets	1,543	6,881	6,840	7,061	12,542	11,952	11,326
Total Assets	12,843	21,368	24,748	32,361	36,100	44,637	52,561

Source: Company, MNCL Research estimates

Exhibit 5: Cash Flow Statement

Y/E March (Rs mn)	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Operating profit bef working capital changes	3,136	4,544	5,368	5,778	6,599	8,005	9,686
Trade and other receivables	-153	-593	-301	343	199	120	130
Inventories	-1,517	-1,153	312	-820	-1,562	-1,356	-1,356
Trade payables	2,208	-414	947	718	786	167	245
Changes in working capital	3,674	2,384	6,326	6,019	6,022	6,936	8,705
Direct taxes	-704	-1,082	-1,249	-1,600	-1,369	-1,766	-2,144
Cash flow from operations	2,971	1,302	5,077	4,419	4,653	5,169	6,562
Net Capex	-247	-188	-107	-300	-156	-349	-356
Others	-1,355	-8,745	-3,165	-6,527	751	-707	1,344
Cash flow from investments	-1,602	-8,933	-3,272	-6,827	595	-1,056	987
FCF	2,724	1,114	4,970	4,119	4,497	4,820	6,205
Increase/(decrease) in debt	2,564	-73	-67	3,296	0	0	0
dividend	-177	-254	-279	-318	0	0	0
Others	-52	3,658	-316	-103	-156	-127	-105
Cash flow from financing	2,335	3,331	-662	2,875	-156	-127	-105
Net change in cash	3,703	-4,300	1,143	467	5,091	3,986	7,444

Source: Company, MNCL Research estimates

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

About the Research Entity

Monarch Network Capital Limited (defined as “**MNCL**” or “**Research Entity**”) a company duly incorporated under the Companies Act, 1956 (CIN: L64990GJ1993PLC120014) having its registered office at Unit No. 803-804A, 8th Floor, X-Change Plaza, Block No. 53, Zone 5, Road- 5E, Gift City, Gandhinagar -382355, Gujarat is regulated by the Securities and Exchange Board of India (“**SEBI**”) and is engaged in the business of Stock Broking, Alternative Investment Funds, Portfolio Management Services, Merchant Banking, Research Analyst, Depository Participant, Mutual Fund Distribution, and other related activities.

General Disclaimer:

This Research Report (hereinafter called “Report”) has been prepared by MNCL in the capacity of a Research Analyst having SEBI Registration No. INH000000644 and Enlistment no. 5039 with BSE and distributed as per SEBI (Research Analysts) Regulations, 2014 and is meant solely for use by the recipient and is not for circulation. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through MNCL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. MNCL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on MNCL for certain operational deviations in ordinary/routine course of business. MNCL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities during the last 5 years; nor has its certificate of registration been cancelled by SEBI.


The information contained herein is from publicly available data, internally developed data or other sources believed to be reliable by MNCL. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The reader assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved) and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors. This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose.

The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. MNCL reserves the right to make modifications and alterations to this statement as may be required from time to time. MNCL or any of its associates / group companies, officers, employee's and directors shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MNCL is committed to providing independent and transparent recommendation to its clients. Neither MNCL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of MNCL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of MNCL and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

MNCL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the MNCL to present the data. In no event shall MNCL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the MNCL through this report.

MNCL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. MNCL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with MNCL. Registration granted by SEBI and certification from NISM in no way guarantee performance of MNCL or provide any assurance of returns to investors and clients.

MNCL or its associates may have received compensation from the subject company in the past 12 months. MNCL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. MNCL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. MNCL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. MNCL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. MNCL and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. A graph of daily closing prices of the securities is also available at www.nseindia.com.



The recommendations in the reports are based on 12-month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. The stocks always carry the risk of being upgraded to buy or downgraded to a hold, reduce or sell. The opinions expressed in the reports are subject to change but we have no obligation to tell our clients when our opinions or recommendations change. The report is non-inclusive and do not consider all the information that the recipients may consider material to investments. The report is issued by MNCL without any liability/undertaking/commitment on the part of itself or any of its entities. MNCL, its directors, employees, and affiliates shall not be liable for direct, indirect, or consequential losses (including lost profits), Errors, omissions, or delays in data dissemination and decisions made based on these Materials. The Artificial Intelligence tools may have been used only to an extent of supporting tool. All the data/ information contained in the report has been independently verified by the Research Analyst.

Disclaimers in respect of jurisdiction: This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MNCL

and associates, subsidiaries / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions.

Statements of ownership and material conflicts of interest

Answers to the Best of the knowledge and belief of MNCL/ its Associates/ Research Analyst who is preparing this report:	Yes/No
whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest;	No
whether the research analyst or research entity or its associates or relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	No
whether the research analyst or research entity or his associate or his relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance;	No
whether the research analyst has served as an officer, director or employee of the subject company;	No

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Investors are advised to refer to SEBI's investor education website (<https://investor.sebi.gov.in>) for guidance on understanding research reports and market risks.

Additional Disclaimers

For U.S. persons only: The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Research reports are intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, MNCL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be affected through Marco Polo or another U.S. registered broker dealer.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.

MNCL operates under strict regulatory oversight and holds the following licenses and registrations:

Member (Member of NSE, BSE, MCX and NCDEX).
 SEBI Registration No.: INZ000008037
 Depository Participant (DP)
 CDSL DP ID: 35000
 NSDL-DP ID: IN303052
 SEBI Registration No.: IN-DP-278-2016

Portfolio Manager SEBI Registration No.: INP000006059
Research Analyst SEBI Registration No. INH00000644
Research Analyst BSE Enlistment No. 5039
Merchant Banker SEBI Registration No. INM000011013
Alternative Investment Fund SEBI Registration No. IN/AIF3/20-21/0787
Mutual Fund Distributor AMFI REGN No. ARN-8812
Point of Presence for National Pension System. - 6092018
Website: www.mnclgroup.com
Investor Grievance Email ID: grievances@mnclgroup.com
Broking and Research Analyst Compliance Officer Details: Mr Nikhil Parikh
022-30641600; Email ID: compliance@mnclgroup.com
Monarch Network Capital Limited (CIN: L64990GJ1993PLC120014)
Registered Office:
Unit No. 803-804A, 8th Floor, X-Change Plaza, Block No. 53,
Zone 5, Road- 5E, Gift City, Gandhinagar -382355, Gujarat